Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

INTRODUCTION: Patients with active rheumatoid arthritis (RA) despite anti–tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physic...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrold, Leslie R., Reed, George W., Magner, Robert, Shewade, Ashwini, John, Ani, Greenberg, Jeffrey D., Kremer, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574482/
https://www.ncbi.nlm.nih.gov/pubmed/26382589
http://dx.doi.org/10.1186/s13075-015-0776-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574482/
https://www.ncbi.nlm.nih.gov/pubmed/26382589
http://dx.doi.org/10.1186/s13075-015-0776-1

Ejemplares similares